(S)-Thalidomide

• UNSPSC Description:

  (S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects[1][2][3]. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN) [4].

• Target Antigen:

  Apoptosis; Autophagy; Ligands for E3 Ligase; Molecular Glues

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;PROTAC

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/s-thalidomide.html

• Solubility:

  DMSO : 83.33 mg/mL (ultrasonic)

• Smiles:

  O=C1N([C@@H](CC2)C(NC2=O)=O)C(C3=C1C=CC=C3)=O

• Molecular Weight:

  258.23

• References & Citations:

  [1]Stephens TD. The effect of thalidomide in chicken embryos. Birth Defects Res A Clin Mol Teratol. 2009 Aug;85(8):725-31.|[2]Murphy S, et al. Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. J Pharm Pharmacol. 2007 Jan;59(1):105-14.|[3]Liu WM, et al. s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J. 2004;5(3):247-54.|[4]Tokunaga E, et al. Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers. Sci Rep. 2018 Nov 20;8(1):17131.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  841-67-8